Loading clinical trials...
Loading clinical trials...
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Conditions
Interventions
Mogamulizumab
Locations
16
United States
City of Hope National Medical Center
Duarte, California, United States
University of California Irvine
Irvine, California, United States
Stanford Cancer Center
Stanford, California, United States
Tulane University School of Medicine
New Orleans, Louisiana, United States
New York Presbyterian Hospital
New York, New York, United States
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Start Date
August 16, 2021
Primary Completion Date
May 1, 2025
Completion Date
May 1, 2025
Last Updated
April 25, 2024
Lead Sponsor
Kyowa Kirin, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions